BRACAnalysis CDx
Germline BRCA1/2 companion diagnostic used for treatment selection across specified BRCA-associated cancer indications.
- Developer
- Myriad Genetics
- Intended use
- Other
- Cancer scope
- Breast cancer, Ovarian cancer, Pancreatic cancer, Prostate cancer
- Specimen
- Whole blood
- Molecular modality
- DNA mutation
- Current version
- Current BRACAnalysis CDx configuration (2026-09)
- Evidence context
- 0 structured studies · 0 indexed performance results · 2 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.